L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity.
L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity.
复制标题
L-cycloserine 是一种鞘脂生物合成抑制剂，可抑制 HIV-1 细胞病变效应、复制和感染性。
DOI：
10.1097/00042560-199602010-00004
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
Rubinstein,A
中科院分区：
文献类型：
--
作者：
Mizrachi,Y;Lev,M;Harish,Z;Sundaram,SK;Rubinstein,A
与与HIV-1生命周期相互作用的治疗方式相比，通过干扰宿主细胞成分减少病毒产生或防止病毒传播的药物不太可能诱导耐药性。两个特征使得L-环丝氨酸（L-CS）成为这类候选药物：（a）L-CS是鞘脂途径的有效抑制剂（B）鞘脂、半乳糖苷和硫苷脂已被其他人证明与gp 120结合。在一项可行性和有效性研究中，我们发现L-CS可抑制HIV-1在CD 4+淋巴细胞系（CEM）中的复制，如合胞体形成减少、HIV-1感染细胞数量减少和p24蛋白产生减少所证实。这一观察结果可能会导致一种治疗HIV-1感染的新策略。
Drugs that reduce viral production or prevent viral spread by interference with the host's cellular components are unlikely to induce resistance, in contrast to treatment modalities that interact with the HIV-1 life cycle. Two features make L-cycloserine (L-CS) a candidate drug of this kind:(a) L-CS is a potent inhibitor of the sphingolipid pathway (b) sphingolipids, galactocerebrosides, and sulfatides have been shown, by others, to bind gp120. In a feasibility and efficacy study, we have found that L-CS inhibits HIV-1 replication in a CD4+ lymphoid cell line (CEM) as documented by the reduction of syncytium formation, the number of HIV-1 infected cells, and p24 protein production. This observation may lead to a new strategy for the treatment of HIV-1 infection.